Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Roy

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Bioorganic & Medicinal Chemistry Letters|April 2, 2013
Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinomeStephen M Lynch, Javier DeVicente, Johannes C Hermann, et al.
Science (New York, N.Y.)|August 16, 2005
Complete genome sequence and lytic phase transcription profile of a CoccolithovirusWilliam H Wilson, Declan C Schroeder, Michael J Allen, et al.
Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Bioorganic & Medicinal Chemistry Letters|April 2, 2013
Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinomeStephen M Lynch, Javier DeVicente, Johannes C Hermann, et al.
Science (New York, N.Y.)|August 16, 2005
Complete genome sequence and lytic phase transcription profile of a CoccolithovirusWilliam H Wilson, Declan C Schroeder, Michael J Allen, et al.
Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.
Pageof 2